First Community Trust NA Buys 455 Shares of Hologic, Inc. (NASDAQ:HOLX)

First Community Trust NA grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 2.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,165 shares of the medical equipment provider’s stock after buying an additional 455 shares during the quarter. Hologic makes up 0.9% of First Community Trust NA’s holdings, making the stock its 25th biggest holding. First Community Trust NA’s holdings in Hologic were worth $1,237,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic during the 3rd quarter valued at $25,000. General Partner Inc. bought a new position in Hologic in the fourth quarter valued at about $26,000. Groupama Asset Managment grew its holdings in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. acquired a new position in shares of Hologic in the second quarter valued at approximately $37,000. Finally, First Horizon Advisors Inc. raised its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on HOLX shares. Jefferies Financial Group started coverage on shares of Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Monday. Royal Bank of Canada raised their price objective on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.75% of the stock is owned by company insiders.

Hologic Trading Down 0.1 %

HOLX opened at $70.20 on Wednesday. The company has a market cap of $15.93 billion, a P/E ratio of 21.08, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. The company has a fifty day moving average price of $75.61 and a two-hundred day moving average price of $78.53. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1-year low of $69.46 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company posted $0.89 EPS. The firm’s revenue was up 4.5% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.